CD30 is expressed in neoplastic mast cells in a majority of patients with advanced systemic mastocytosis (85%), whereas in most patients with indolent systemic mastocytosis only a few if any mast cells stained positive for this marker. Here, TNFRSF8 is linked to systemic mastocytosis.